Andere Sprachen BioLineRx Ltd.

Aktien

A1CZAB

IL0011015182

BLRX

Markt geschlossen - TEL AVIV STOCK EXCHANGE Andere Börsenplätze 14:49:41 02.06.2024			% 5 Tage	% 1. Jan.
18.3 ^ILa	+1.67%		+5.78%	-52.09%

30.05.	BioLineRx Ltd. gibt eine Vereinbarung mit dem St. Jude Children's Research Hospital, Inc. über eine klinische Studie zur Untersuchung von Motixafortide zur Mobilisierung von CD34+ hämatopoetischen Stammzellen für gentherapeutische Anwendungen bei Sichelzellanämie bekannt	CI
28.05.	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	30.05.
Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024	28.05.
BioLineRx Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	28.05.
BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology	24.05.
BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	17.04.
BioLineRx Shares Fall After $6 Million Registered Direct Offering	01.04.
Transcript : BioLineRx Ltd., Q4 2023 Earnings Call, Mar 26, 2024	26.03.
BioLineRx Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production	04.03.
Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer	28.02.
BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?	16.02.
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	21.12.
BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director	12.12.
Transcript : BioLineRx Ltd., Q3 2023 Earnings Call, Nov 20, 2023	20.11.
BioLineRx Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	20.11.
BioLineRx Signs License Agreement With GloriaBio for Multiple Myeloma Drug	12.10.23
Biolinerx Ltd. Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment	12.10.23
BioLineRx Says Pilot Phase of Combination Trial With Motixafortide in First-Line Pancreatic Cancer Yields 'Encouraging' Data	28.09.23
Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer	28.09.23
BIOLINERX LTD. : HC Wainwright maintient sa recommandation à l'achat	15.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioLineRx Ltd.

Aktien

A1CZAB

IL0011015182

BLRX

Andere Sprachen

Filter